MedPath

Cardiovascular Autonomic Neuropathy in Patients With Type 1 Diabetes Mellitus.

Not Applicable
Completed
Conditions
Diabetes Mellitus, Type 1
Registration Number
NCT03481374
Lead Sponsor
Hasselt University
Brief Summary

testing of autonomic function and relationship with exercise and Qol in diabetic patients and controls

Detailed Description

Cardiovascular autonomic neuropathy is a common (sub)clinical symptom in persons with type 1 diabetes mellitus. Subjects in this non-commercial, monocentric, interventional study undergo autonomic function tests, a maximal ergospirometry and three questionnaires about the quality of life (EQ-5D-3L), the capacity to do physical activities (IPAQ) and the experience of possible symptoms of autonomic dysfunction in daily life (SCOPA-AUT). In this way the influence of type 1 diabetes mellitus on the quality of life, the exercise capacity and the autonomic function can be studied.

The primary aim of this study investigates the potential correlations between the severity of diabetic cardiovascular autonomic neuropathy (DCAN) and both the quality of life and the exercise capacity. As a secondary aim, the influences of gender, age, number of years since diagnosis of type 1 diabetes mellitus, VO2 max predicted, maximal heart rate during exercise, minimal heart rate in rest, maximal RER (Respiratory exchange ratio) and relevant interaction terms are studied.

In total 52 test subjects with type 1 diabetes mellitus and 27 matched control subjects are selected to participate in this study.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
79
Inclusion Criteria
  • Type 1 diabetes mellitus (only for the group of subjects with diabetes mellitus)
  • At least two years with diagnosis of type 1 diabetes mellitus
  • Subject is in a stable condition
  • No hospitalization for any reason in the past three months
  • 18 years or older
  • Being capable of doing physical activities
  • Understand the study design and the informed consent
  • Sign the informed consent
  • No simultaneously participation to another study
  • Being capable of moving to the study center
Exclusion Criteria
  • Uncontrolled hypertension, atrial fibrillation and other cardiovascular conditions

  • Severe lung disease

  • Muscle deficiency

  • Medication with influence on the autonomic nervous system:

    • Beta blockers
    • Alfa blockers
    • Antidepressants
    • Non-catecholamines
    • (anti) cholinergic medication

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
VO2 maxday 1

peak oxygen consumption

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Jessa Ziekenhuis

🇧🇪

Hasselt, Belgium

Jessa Ziekenhuis
🇧🇪Hasselt, Belgium

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.